Welcome to our dedicated page for Aura Biosciences news (Ticker: AURA), a resource for investors and traders seeking the latest updates and insights on Aura Biosciences stock.
Aura Biosciences, Inc. (AURA) is a clinical-stage biotechnology company pioneering precision therapies that target solid tumors while preserving critical organ function. This page serves as the definitive source for investors and medical professionals tracking the company's progress in ocular oncology and bladder cancer treatments.
Access real-time updates on clinical trial developments, regulatory milestones, and strategic partnerships. Our curated news collection includes press releases covering drug candidate advancements (including lead program bel-sar), financial disclosures, and scientific presentations—all essential for evaluating AURA's position in targeted cancer therapeutics.
Key content categories include clinical trial phase updates, FDA designation announcements, collaborative research initiatives, and financial performance reports. The company's innovative molecular surgery approach—combining direct tumor targeting with immune activation—is reflected across all coverage.
Bookmark this page for streamlined monitoring of AURA's progress in vision-preserving ocular melanoma treatments and organ-sparing bladder cancer therapies. Check regularly for authoritative updates on this clinical-stage innovator's journey through the drug development pipeline.
Aura Biosciences (NASDAQ: AURA) announced encouraging interim Phase 2 data for its first virus-like drug conjugate, belzupacap sarotalocan (AU-011), targeting early-stage choroidal melanoma. The data, presented at the American Academy of Ophthalmology 2022 Annual Meeting, showed a significant reduction in tumor growth rates (-0.296 mm/yr, p = 0.0007) and an 88.9% tumor control rate after three cycles of treatment. The therapy demonstrated favorable safety and a potential for vision preservation in patients lacking treatment options. A virtual Investor Day was scheduled to discuss these findings further.
Aura Biosciences Inc. (NASDAQ: AURA) has announced the dosing of the first patient in a Phase 1 clinical trial of belzupacap sarotalocan, aimed at treating Non-Muscle Invasive Bladder Cancer (NMIBC). This trial marks a significant milestone in urologic oncology, addressing a high unmet medical need. The trial will enroll 23 patients to evaluate the safety and tolerability of the treatment. Previously, the FDA granted Fast Track designation for this candidate, facilitating more frequent consultations regarding its clinical development.
Aura Biosciences (NASDAQ: AURA) will present data from its Phase 2 trial for belzupacap sarotalocan (AU-011) at the American Academy of Ophthalmology (AAO) Annual Meeting, running from September 30 to October 3, 2022. The trial targets early-stage choroidal melanoma. A virtual Investor Day is scheduled for October 3, featuring discussions with ocular oncology experts about safety, efficacy results, and potential combinations with immune checkpoint inhibitors. The company aims to develop AU-011 for various oncology treatments, including ocular cancers.
Aura Biosciences Inc. (NASDAQ: AURA) recently announced that Phase 2 data for its first virus-like drug conjugate (VDC), belzupacap sarotalocan (AU-011), will be presented at the ESMO 2022 Congress, taking place from September 9-13 in Paris. The presentation will focus on the safety of suprachoroidal administration for treating early-stage choroidal melanoma. The company aims to enhance treatment options for this severe form of eye cancer, currently in a dose escalation trial. Additional developments are planned for other oncology applications.
Aura Biosciences Inc. (NASDAQ: AURA) announced recent advancements in its leading candidate, belzupacap sarotalocan (AU-011), aimed at treating early-stage choroidal melanoma. Presentations at the EURETINA Congress will showcase interim safety results from a Phase 2 trial and final efficacy data from a Phase 1b/2 trial. The ongoing development focuses on both choroidal melanoma and its metastatic counterpart. Aura plans to submit an IND for choroidal metastases in the second half of 2022, emphasizing the drug's potential in ocular oncology.
Aura Biosciences (NASDAQ: AURA) reported significant advancements in its clinical pipeline for belzupacap sarotalocan, aiming to treat non-muscle invasive bladder cancer (NMIBC) and early-stage choroidal melanoma. The company is set to dose the first patient in the Phase 1 trial for NMIBC in Q3 2022 and initiate a pivotal trial for choroidal melanoma in Q4 2022. Aura received FDA Fast Track designation for NMIBC, enhancing its development strategy. Financially, the company reported a net loss of $13.5 million for Q2 2022, with cash reserves expected to fund operations into 2024.
Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology firm, announced participation in a fireside chat at the 2022 Hybrid BTIG Biotechnology Conference on August 8, 2022, at 9:00 a.m. ET. The chat will feature CEO Elisabet de los Pinos and CFO Julie Feder. Aura is developing a novel class of virus-like drug conjugates (VDCs) for oncology, including its leading candidate, belzupacap sarotalocan (AU-011), aimed at treating ocular cancers. The company is also pursuing other applications in cancer therapy.
Aura Biosciences, Inc. (NASDAQ: AURA) has received Fast Track designation from the FDA for its drug candidate belzupacap sarotalocan (AU-011), aimed at treating Non-Muscle Invasive Bladder Cancer (NMIBC). This designation facilitates a more efficient development process, enabling frequent communication with the FDA and potential for Priority Review. The planned Phase 1 clinical trial will assess safety and treatment efficacy, with data expected in 2023. Aura also has Fast Track and Orphan Drug designations for AU-011 in choroidal melanoma.
Aura Biosciences Inc. (NASDAQ: AURA) announced results from a retrospective study comparing visual acuity outcomes in early-stage choroidal melanoma patients treated with belzupacap sarotalocan against those receiving plaque radiotherapy. The study indicated significant vision preservation (p = 0.0094) for belzupacap sarotalocan, highlighting the urgent need for effective therapies in this patient population. The Chief Medical Officer emphasized the potential of belzupacap sarotalocan to shift treatment paradigms, with ongoing Phase 2 trials exploring further efficacy.
Aura Biosciences (NASDAQ: AURA) presented data on its virus-like drug conjugate (VDC), belzupacap sarotalocan (AU-011), for treating early-stage choroidal melanoma at the ISOO 2022 Bi-Annual Meeting in the Netherlands. Key findings include updated safety results from a Phase 2 trial using suprachoroidal administration and final efficacy data from a Phase 1b/2 trial with intravitreal administration. Aura plans to finalize the administration route and begin its pivotal program by year's end, underscoring its commitment to vision-preserving therapies.
FAQ
What is the current stock price of Aura Biosciences (AURA)?
What is the market cap of Aura Biosciences (AURA)?
